TABLE 2.
Characteristics of patients at risk for IA in whom serum BG and GM was evaluated
| Characteristic | Proven IA | Probable IA | Possible IA | No IA | Total |
|---|---|---|---|---|---|
| No. of patients | 5 | 3 | 3 | 29 | 40 |
| Age (yr)a | 48 (29-70) | 49 (32-70) | 33 (20-54) | 45 (18-70) | 44 (18-70) |
| Gender (M/F)b | 2/3 | 2/1 | 2/1 | 17/12 | 23/17 |
| No. (%) with underlying diseasec | |||||
| ALL | 2 (66.7) | 2 (5) | |||
| AML | 2 (40) | 2 (66.7) | 1 (33.3) | 4 (13.8) | 9 (22.5) |
| CLL | 1 (20) | 8 (27.5) | 9 (22.5) | ||
| MM | 3 (10.34) | 3 (7.5) | |||
| MDS | 1 (20) | 1 (33.3) | 1 (3.4) | 3 (7.5) | |
| NHL | 1 (20) | 8 (27.6) | 9 (22.5) | ||
| HD | 4 (13.8) | 4 (10) | |||
| SAA | 1 (3.4) | 1 (2.5) | |||
| No. (%) receiving steroids | 3 (60) | 3 (100) | 1 (33.3) | 6 (20.7) | 13 (32.5) |
| Mean duration of neutropenia (days) | 42.8 | 37.33 | 43.6 | 22.44 | 27.7 |
| Range of duration of neutropenia (days) | 10-70 | 27-56 | 26-56 | 6-70 | 6-70 |
| No. of episodes of antifungal therapy | 5 (100) | 3 (100) | 3 (100) | 12 (30) | 23 (57.5) |
| No. of samples (total) | 69 | 36 | 39 | 181 | 325 |
| No. of samples/episode | 13.8 | 12 | 12.66 | 6.24 | 8.12 |
| No.d (%) of positive episodes | 5 (100) | 2 (66) | 1 (33) | 3 (10.34) | 11 (27.5) |
| No. (%) of positive samples for BG | 35 (50.7) | 17 (47.2) | 12 (30.7) | 6 (3.3) | 64 (19.7) |
| No. (%) of positive samples for GM | 28 (40.6) | 13 (36.1) | 11 (28.2) | 6 (3.3) | 58 (17.8) |
a
Values in parentheses are ranges.
b
M/F, male/female.
c
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, Chronic lymphocytic leukemia; MM, Multiple myeloma; MDS, Myelodisplastic syndrome; NHL, Non-Hodgkin's lymphoma; HD, Hodgkin disease; SAA, Severe aplastic anemia.
d
Values in parentheses are percentages of patients who received antifungal therapy.